Ebb & Flow

Watchers of Warburg Pincus investments in public biotech companies might think they are seeing a pattern: large stakes, two board seats and an M&A deal on the horizon. Thus, if coincidence isn't at work, it might be reasonable to wonder if Neurogen (NRGN) might have suitors in its future. The company last week raised $100 million in a private placement led by Pincus and Baker Brothers.

Warburg's two most recent investments in public biotechs came in 2001. The firm took a 35% stake in Synaptic when the GPCR play was valued at $60 million, and put $60 million into Triangle when it was valued at $130 million. In both cases, managing directors Jonathan Leff and Stewart Hen took board seats (see "Warburg's Plays").

The firm made tidy profits on both. In late 2002, Lundbeck (CSE:LUN) announced plans to acquire Synaptic for $122.5 million in cash and Gilead (GILD) announced that it was acquiring Triangle for $464 million in cash.

In the NRGN financing, the investor group gained a 42% stake in the company, while Leff and Hen joined the board. The financing more than doubles NRGN's cash - the company had $45.9 million at year end and posted a 2003 operating loss of $32.9 million.

NRGN is using its Accelerated Intelligent Drug Discovery system to design, model, synthesize and screen compounds. The company's lead compound is NGD 2000-1, an oral C5a antagonist in Phase II testing for rheumatoid arthritis (RA). NRGN, which was founded in 1987, also has multiple deals with pharma: an insomnia collaboration with Pfizer (PFE), a depression/anxiety deal with Aventis (AVE), and a pain partnership with Merck (MRK).

A not-so-new order

The management changes announced last week at Pacific Growth Equities simply formalize how the organization has been run for the past several years. Thomas

Read the full 2955 word article

User Sign In